Koehler, Maria
Pfizer (United States)
4 papers on CoChatORCID 0000-0002-4477-9621
Most cited papers
- Verified
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 1,827
- Verified
Palbociclib in hormone-receptor-positive advanced breast cancer
Turner, N. C., Ro, J., André, F., Loi, S., Verma, S., Iwata, H., Harbeck, N., Loibl, S., Huang Bartlett, C., Zhang, K., et al. (2015) · New England Journal of Medicine
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 1,590
- Verified
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 722
- Verified
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor
Scaltriti, M., Chandarlapaty, S., Prudkin, L., Aura, C., Jimenez, J., Angelini, P. D., Sánchez, G., Guzman, M., Parra, J. L., Ellis, C., et al. (2010) · Clinical Cancer Research
HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations
Cited by 151
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free